Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL. Increased lymphocytes in the TME on treatment (OT) compared to baseline (BL). This is an ASCO Meeting Abstract from the ...
IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors. A pan-tumor prospective translational, Irish study, investigating the association of gut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results